• 1
    Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 2004; 306: 9668.
  • 2
    Johansen JS,Cintin C,Jorgensen M,Kamby C,Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995; 31A: 143742.
  • 3
    Rejman JJ,Hurley WL. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem Biophys Res Commun 1988; 150: 32934.
  • 4
    Rejman JJ,Hurley WL,Bahr JM. Enzyme-linked immunosorbent assays of bovine lactoferrin and a 39-kilodalton protein found in mammary secretions during involution. J Dairy Sci 1989; 72: 55560.
  • 5
    Mohanty AK,Singh G,Paramasivam M,Saravanan K,Jabeen T,Sharma S,Yadav S,Kaur P,Kumar P,Srinivasan A,Singh TP. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. J Biol Chem 2003; 278: 1445160.
  • 6
    Johansen JS,Jensen BV,Roslind A,Nielsen D,Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006; 15: 194202.
  • 7
    Morrison BW,Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994; 9: 341726.
  • 8
    Johansen JS,Hvolris J,Hansen M,Backer V,Lorenzen I,Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 5539.
  • 9
    Peltomaa R,Paimela L,Harvey S,Helve T,Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 2001; 20: 1926.
  • 10
    Jensen BV,Johansen JS,Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003; 9: 442334.
  • 11
    Johansen JS,Christensen IJ,Riisbro R,Greenall M,Han C,Price PA,Smith K,Brunner N,Harris AL. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival. Breast Cancer Res Treat 2003; 80: 1521.
  • 12
    Cintin C,Johansen JS,Christensen IJ,Price PA,Sorensen S,Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999; 79: 14949.
  • 13
    Hormigo A,Gu B,Karimi S,Riedel E,Panageas KS,Edgar MA,Tanwar MK,Rao JS,Fleisher M,DeAngelis LM,Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006; 12: 5698704.
  • 14
    Pelloski CE,Lin E,Zhang L,Yung WK,Colman H,Liu JL,Woo SY,Heimberger AB,Suki D,Prados M,Chang S,Barker FG, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006; 12: 393541.
  • 15
    Tanwar MK,Gilbert MR,Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002; 62: 43648.
  • 16
    Johansen JS,Drivsholm L,Price PA,Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 2004; 46: 33340.
  • 17
    Dupont J,Tanwar MK,Thaler HT,Fleisher M,Kauff N,Hensley ML,Sabbatini P,Anderson S,Aghajanian C,Holland EC,Spriggs DR. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004; 22: 33309.
  • 18
    Schmidt H,Johansen JS,Gehl J,Geertsen PF,Fode K,von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006; 106: 11309.
  • 19
    Schmidt H,Johansen JS,Sjoegren P,Christensen IJ,Sorensen BS,Fode K,Larsen J,von der Maase H. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 2006; 24: 798804.
  • 20
    Nutt CL,Betensky RA,Brower MA,Batchelor TT,Louis DN,Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 2005; 11: 225864.
  • 21
    Roslind A. YKL-40 expression in benign and malignant lesions of the breast. Proc ASCO 2005; 9665A.
  • 22
    Fahy BN,Bold RJ,Schneider PD,Khatri V,Goodnight JE,Jr. Cost-benefit analysis of biopsy methods for suspicious mammographic lesions. Arch Surg 2001; 136: 9904. discussion 994–5.
  • 23
    Sauter ER,Ross E,Daly M,Klein-Szanto A,Engstrom PF,Sorling A,Malick J,Ehya H. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997; 76: 494501.
  • 24
    Volck B,Johansen JS,Stoltenberg M,Garbarsch C,Price PA,Ostergaard M,Ostergaard K,Lovgreen-Nielsen P,Sonne-Holm S,Lorenzen I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001; 9: 20314.
  • 25
    Greten FR,Eckmann L,Greten TF,Park JM,Li ZW,Egan LJ,Kagnoff MF,Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 28596.
  • 26
    Junker N,Johansen JS,Andersen CB,Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005; 48: 22331.